IAG Appoints Dr. Christophe Berthoux a Chairman to the Board

IAG Appoints Dr. Christophe Berthoux a Chairman to the Board

IAG Appoints Dr. Christophe Berthoux a Chairman to the Board

IAG, Image Analysis Group, the innovator in medical imaging solutions for drug development, announces the appointment of Dr. Christophe Berthoux as Chairman to the Board.

Dr. Berthoux joined IAG to develop the Company’s people and growth strategies. Prior to this role, Dr. Berthoux served as the Chief Executive at Synexus Limited, which was acquired by Jaguar, a holding company of Pharmaceutical Product Development (PPD).

Dr. Berthoux has extensive experience in the international clinical trials sector and has worked both in the United States and Europe. He has spent all his 28-year career in the Clinical Research industry and served as a Chief Commercial Officer and Executive Vice President of Global Sales & Marketing for Charles River Laboratories International Inc., since September 2008.

Between 2010 and 2017, he served as CEO of multinational company Synexus, which was purchased by the private equity firm for £178m (approximately $258 million) in June 2016.

Prof. Richard Barker, who chaired the Board since 2014 and was instrumental in establishing IAG’s Bio-Partnering, Strategy and Operations divisions, will remain on the Company’s Board as a Non-Executive Director.

“We are pleased to welcome Christophe”, said Dr. Olga Kubassova, the CEO of IAG, “Christophe’s extensive experience in leading global commercial teams and international business growth will be incredibly beneficial to IAG, as we look to drive successful growth and international expansion.” 

Dr. Berthoux  was effective September 1, 2018.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin